NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

Core Insights - NewAmsterdam Pharma has appointed Adele Gulfo as an independent director to its Board of Directors, bringing over 30 years of experience in the healthcare industry [1][2][4] - The company is preparing for the potential launch of obicetrapib, an oral, non-statin medicine aimed at lowering LDL-C for patients at risk of cardiovascular disease [2][5] Company Overview - NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, specifically targeting patients with elevated LDL-C who do not respond well to existing treatments [5] - The company is investigating obicetrapib as a cholesterol ester transfer protein (CETP) inhibitor, which is being tested in multiple Phase 3 trials [5] Leadership and Experience - Adele Gulfo has a strong background in commercial leadership, having previously held executive roles at Sumitomo Pharma America, Sumitovant Biopharma, and Pfizer, where she contributed to the launch of major brands like LIPITOR® and CRESTOR® [2][3] - Her expertise in global strategy and operations is expected to be crucial for NewAmsterdam as it finalizes its commercial strategy and prepares for its first product launch [2][4] Clinical Development - NewAmsterdam has reported positive outcomes from its three pivotal Phase 3 clinical trials, indicating progress in its development efforts [4]